Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells
Authors:
Open Access
- 15 September 2025
- journal article
- Published by Wiley in FEBS Letters
- Vol. 599 (23) , 3524-3536
Abstract
The protective effects of imeglimin, a recently approved antidiabetic agent, against liver fibrosis have not been previously evaluated. In this study, we demonstrated that 8‐week administration of imeglimin attenuated immune cell infiltration and reduced collagen deposition, improving fibrosis stage in a thioacetamide‐induced murine model. Further analyses focusing on hepatic stellate cells (HSCs), the primary effector cells in fibrogenesis, revealed decreased expression of α‐smooth muscle actin and desmin, markers of HSC activation. Mechanistically, a clinically relevant low concentration (10 μ m ) of imeglimin reduced intracellular vesicular ATP accumulation and subsequently suppressed ATP release from HSCs in vitro . These findings suggest that imeglimin may exert anti‐inflammatory and antifibrotic effects by inhibiting vesicular ATP release and ATP‐mediated purinergic signaling. Impact statement: At clinically relevant doses, imeglimin inhibits vesicular ATP release from hepatic stellate cells, reducing inflammatory infiltration and fibrotic collagen accumulation. These findings support its evaluation as a combined metabolic and antifibrotic therapy for MASLD and other chronic liver conditions.Keywords
Funding Information
- Japan Society for the Promotion of Science (KAKENHI 22K08663)
This publication has 21 references indexed in Scilit:
- Imeglimin attenuates NLRP3 inflammasome activation by restoring mitochondrial functions in macrophagesJournal of Pharmacological Sciences, 2024
- Protocol for enrichment, purification, and cytocentrifugation of mouse liver endothelial cellsSTAR Protocols, 2023
- A purinergic mechanism underlying metformin regulation of hyperglycemiaiScience, 2023
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewHepatology, 2023
- Optimization of the isolation procedure and culturing conditions for hepatic stellate cells obtained from mouseBioscience Reports, 2021
- Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetesDiabetes, Obesity and Metabolism, 2020
- Contemporary Epidemiology of Chronic Liver Disease and CirrhosisClinical Gastroenterology and Hepatology, 2020
- A review of phenformin, metformin, and imegliminDrug Development Research, 2020
- Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respirationCell Death Discovery, 2016
- Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in miceLaboratory Investigation, 2008